Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease
about
Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end productsInvolvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategiesAdvanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents.The role of receptor for advanced glycation endproducts (RAGE) in infection.Do statins have a role in reduction/prevention of post-PCI restenosis?The alarmin functions of high-mobility group box-1 and IL-33 in the pathogenesis of systemic lupus erythematosus.NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links.Dietary consumption of advanced glycation end products and risk of metabolic syndrome.Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.Rutin Inhibits Neuroinflammation and Provides Neuroprotection in an Experimental Rat Model of Subarachnoid Hemorrhage, Possibly Through Suppressing the RAGE-NF-κB Inflammatory Signaling Pathway.Soluble receptor for advanced glycation end products independently predicts cardiometabolic syndrome in Latino youth.Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) – intra- and inter-individual variability in chronic hemodialysis patientsLow maternal serum matrix metalloproteinase (MMP)-2 concentrations are associated with preterm labor and fetal inflammatory responseDetection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot study
P2860
Q26861308-74823C2D-9A7C-47BC-B0F5-C154559EFE8EQ34728267-B29A16E4-6ED4-41A3-BEF9-F056536E86B5Q34981419-87C81794-EF5F-43CA-821E-6EBF5CC52DD0Q37569775-924FA313-3C60-4E6C-A24A-3A94506DD109Q37860412-40618B80-6034-428C-A05F-6BB759752561Q37941867-1F7A575F-947B-4878-98A8-31BB388866F3Q38131032-3D24FAE6-050D-48E7-8770-CCDE279FBD59Q38227386-8DAB4A8C-A2B6-4060-9449-0C6A84471107Q40018926-67479E4D-C112-4CD4-BD58-0404C1F99CD2Q41789363-06D535F2-1D8C-44ED-9EDA-6706DD1BE3ABQ47994395-BF4E5F0B-A285-4A4C-81F0-66944E1082F4Q48912915-24862C44-5883-4E19-8BC9-5A77C366863AQ51178601-387BBDF7-4F16-4021-AA04-72263A407044Q57825168-76888D36-73AF-462B-BAC9-BDD2452E0E18Q57825219-56F43578-A494-4187-9281-287B49217946Q57825263-6E50B286-8FB9-4556-AF81-151EAE5DD275
P2860
Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease
description
im Mai 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2005
@uk
name
Soluble Levels of Receptor for ...... E) and Coronary Artery Disease
@en
Soluble Levels of Receptor for Advanced Glycation Endproducts
@nl
type
label
Soluble Levels of Receptor for ...... E) and Coronary Artery Disease
@en
Soluble Levels of Receptor for Advanced Glycation Endproducts
@nl
prefLabel
Soluble Levels of Receptor for ...... E) and Coronary Artery Disease
@en
Soluble Levels of Receptor for Advanced Glycation Endproducts
@nl
P1476
Soluble levels of receptor for ...... : the next C-reactive protein?
@en
P2093
Ann Marie Schmidt
Evis Harja
P304
P356
10.1161/01.ATV.0000164804.05324.8B
P407
P577
2005-05-01T00:00:00Z